FluMos-v1:
Universal Influenza Vaccine Candidate

- NIH launches Phase 1 Clinical Trial of FluMos-v1
  - FluMos-v1 is an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains that was developed by NIAID scientists and collaborators at the University of Washington
  - **Purpose:** To assess the safety and immunogenicity of FluMos-v1
  - **Participants:** Up to 35 participants between 18 and 50 years old
  - **Location:** NIH Clinical Center, Bethesda, MD
Long-term effects of COVID are real. Join the search for answers.

Have questions about the long-term health effects of the virus? Start by learning about PASC.

 https://recovercovid.org/
Notice of Special Interest (NOSI)

- **Purpose:** To solicit community-engaged research to:
  1) Evaluate intervention strategies (e.g., expand reach, access) to facilitate vaccination uptake in clinical and community contexts; and
  2) Address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations at high risk and likely to experience vaccine hesitancy.

- **Awards:** For example, National Institute on Minority Health and Health Disparities (NIHMD) recently awarded 5 research grants totaling $14.5 million over 5 years for these grants, subject to available funds.

NIH Clinical Trial Evaluating Mixed COVID-19 Vaccine Schedules Begins
NIH Launches Study of Third COVID-19 Vaccine Dose in Kidney Transplant Recipients

Trial Will Assess Antibody Response in People Who Did Not Respond to Two-Dose Regimen
Novavax is conducting a pediatric expansion of its Phase 3 clinical trial for NVX-CoV2373, the company’s recombinant protein vaccine candidate against COVID-19.

- Enrolling up to 3,000 adolescents aged 12-17 across up to 75 sites, including 8 COVID-19 Prevention Network (CoVPN) sites.

- Ancillary nasal swab study called SNIFF (Swab your Nose to Find inFection) to assess asymptomatic viral shedding of SARS-CoV-2.
NIH Begins Study of COVID-19 Vaccination During Pregnancy and Postpartum

*Researchers Will Evaluate Antibody Responses in Vaccinated Participants and Their Infants*

Credit: NIAID